Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

about

Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

Item

http://www.wikidata.org/entity/Q46403959

description

1994 nî lūn-bûn

@nan

1994年の論文

@ja

1994年学术文章

@wuu

1994年学术文章

@zh

1994年学术文章

@zh-cn

1994年学术文章

@zh-hans

1994年学术文章

@zh-my

1994年学术文章

@zh-sg

1994年學術文章

@yue

1994年學術文章

@zh-hant

name

Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

@en

Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

@nl

type

Item

label

Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

@en

Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

@nl

prefLabel

Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

@en

Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

@nl

P1476

Macromolecular complex assembly of prothrombinase is a central process of thrombosis.

@en

P2093

Hollenbach S

http://www.w3.org/2001/XMLSchema#string

Sinha U

http://www.w3.org/2001/XMLSchema#string

Wolf DL

http://www.w3.org/2001/XMLSchema#string

P2860

Cofactor proteins in the assembly and expression of blood clotting enzyme complexes

Activation of human factor X (Stuart factor) by a protease from Russell's viper venom

Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone

Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder.

Rationale for development of low-molecular-weight heparins and their clinical potential in the prevention of postoperative venous thrombosis.

Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.

Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.

Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.

Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis.

Expression, purification, and characterization of inactive human coagulation factor Xa (Asn322Ala419).

P304

32-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1749-6632.1994.TB12028.X

http://www.w3.org/2001/XMLSchema#string

P478

714

http://www.w3.org/2001/XMLSchema#string

P577

1994-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8017790

http://www.w3.org/2001/XMLSchema#string

P921

macromolecule